Screener
Outset Medical, Inc. OM Cost Of Revenue — Allocated Share Based Compensation Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Outset Medical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Outset Medical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338432
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Cost of revenue | $77 | $186 | $188 | $303 |
| Research and development | 594 | 750 | 1,414 | 1,309 |
| Sales and marketing | 416 | 933 | 874 | 1,412 |
| General and administrative | 1,609 | 1,627 | 3,673 | 3,449 |
| Total stock-based compensation expense | $2,696 | $3,496 | $6,149 | $6,473 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Outset Medical, Inc.'s cost of revenue — allocated share based compensation expense?
- Outset Medical, Inc. (OM) reported cost of revenue — allocated share based compensation expense of $77K in Q2 2026.
- What does cost of revenue — allocated share based compensation expense mean?
- This metric represents the portion of share-based compensation expenses specifically attributed to the cost of revenue for the company's dialysis technology and services. It reflects the non-cash personnel costs associated with employees directly involved in the manufacturing, assembly, or service delivery of the Tablo system. Monitoring this expense helps investors understand the underlying labor-related costs of production and the impact of equity-based incentives on gross margin performance.
Ask your AI about Outset Medical, Inc.'s cost of revenue — allocated share based compensation expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude